Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05289167 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 29, 2026 (before its estimated August 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Active, Not Recruiting to Recruiting Primary completion date: Dec 2025 to Aug 2026 · Completion date: Dec 2027 to Aug 2028 · Eligibility criteria revised · 1 morev8 Show 4 more changesShow less
    • Primary completion date: Dec 2025 to Aug 2026
    • Completion date: Dec 2027 to Aug 2028
    • Eligibility criteria revised
    • Site details revised

    See this version in full on ClinicalTrials.gov ↗

  2. Lead sponsor: NYU Langone Health to Northwell Health Primary completion date: Dec 2024 to Dec 2025 · Completion date: Dec 2026 to Dec 2027 · Study site revised · 1 morev7 Show 4 more changesShow less
    • Primary completion date: Dec 2024 to Dec 2025
    • Completion date: Dec 2026 to Dec 2027
    • Study site revised
    • Study title shortened, about 9 words

    See this version in full on ClinicalTrials.gov ↗

  3. Trial status: Recruiting to Active, Not Recruiting Site details revisedv6 Show 1 more changeShow less
    • Site details revised
  4. Site contact updatedv5
  5. Primary completion date: Mar 2024 to Dec 2024 Completion date: Mar 2024 to Dec 2026v4 Show 1 more changeShow less
    • Completion date: Mar 2024 to Dec 2026
Show 2 earlier versionsHide 2 earlier versions
  1. Re-verified, no change to tracked fieldsv3
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Mar 11, 2022 to Mar 13, 2022 · Site details revised · Study title shortened, about 4 wordsv2 Show 3 more changesShow less
    • Start date changed from estimate of Mar 11, 2022 to Mar 13, 2022
    • Site details revised
    • Study title shortened, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase I-II clinical trial. Adult subjects with hematological malignancies undergoing allogeneic HSCT from an HLA matched sibling or ≥7 out of 8 allele level HLA matched unrelated donor are eligible for the study if they meet the criteria defined in our standard operation procedures (SOPs), meet all inclusion criteria, and do not satisfy any exclusion criteria. Subjects will receive a standard of care conditioning regimen. Subjects will receive investigational PTCy, investigational bortezomib and investigational abatacept as GvHD prophylaxis.
Trial Details
NCT Number NCT05289167
Lead Sponsor Northwell Health
Conditions Graft-versus-host Disease
Enrollment 74 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov